Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

Phase 2

Completed

Conditions: Atrial Fibrillation
Atrial Flutter

First Posted Date: 2005-10-05

Last Posted Date: 2012-05-08

Lead Sponsor: Sanofi

Target Recruit Count: 673

Registration Number: NCT00233441

Locations: 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study

Phase 2

Completed

Conditions: Inflammatory Bowel Disease
Ulcerative Colitis

First Posted Date: 2005-10-04

Last Posted Date: 2008-12-10

Lead Sponsor: Sanofi

Target Recruit Count: 307

Registration Number: NCT00232258

Locations: 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

Phase 2

Completed

Conditions: Atrial Fibrillation
Atrial Flutter

First Posted Date: 2005-10-04

Last Posted Date: 2012-05-08

Lead Sponsor: Sanofi

Target Recruit Count: 150

Registration Number: NCT00232310

Locations: 🇵🇹
Sanofi-Aventis Administrative Office, Porto Salvo, Portugal

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS

Phase 2

Completed

Conditions: Arrhythmia
Tachycardia, Ventricular
Ventricular Fibrillation

First Posted Date: 2005-10-04

Last Posted Date: 2012-05-08

Lead Sponsor: Sanofi

Target Recruit Count: 153

Registration Number: NCT00232297

Locations: 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Phase 3

Completed

Conditions: Tumor Lysis Syndrome
Cancer
Hyperuricemia

Interventions: Drug: Rasburicase (SR29142)
Drug: Allopurinol

First Posted Date: 2005-09-30

Last Posted Date: 2010-01-12

Lead Sponsor: Sanofi

Target Recruit Count: 280

Registration Number: NCT00230178

Locations: 🇺🇸
University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States
🇺🇸
New York Methodist Hospital, Brooklyn, New York, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States

and more 12 locations

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Phase 4

Completed

Conditions: Tumors
Hyperuricemia
Tumor Lysis Syndrome

First Posted Date: 2005-09-30

Last Posted Date: 2009-03-30

Lead Sponsor: Sanofi

Target Recruit Count: 94

Registration Number: NCT00230217

Locations: 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkley, California, United States
🇺🇸
University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States
🇺🇸
University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States

and more 4 locations

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: teriflunomide (HMR1726)

First Posted Date: 2005-09-28

Last Posted Date: 2015-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 147

Registration Number: NCT00228163

Locations: 🇨🇦
Investigational Site Number 12, Montreal, Canada
🇨🇦
Investigational Site Number 11, Montreal, Canada
🇨🇦
Investigational Site Number 17, Vancouver, Canada

and more 13 locations

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

First Posted Date: 2005-09-28

Last Posted Date: 2008-12-23

Lead Sponsor: Sanofi

Target Recruit Count: 564

Registration Number: NCT00228150

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guilford Surrey, United Kingdom

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

Phase 3

Terminated

Conditions: Carotid Artery Plaque
Arteriosclerosis
Obesity
Metabolic Syndrome X

Interventions: Drug: Placebo (for Rimonabant)
Drug: Rimonabant

First Posted Date: 2005-09-28

Last Posted Date: 2016-05-20

Lead Sponsor: Sanofi

Target Recruit Count: 661

Registration Number: NCT00228176

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

First Posted Date: 2005-09-22

Last Posted Date: 2008-12-23

Lead Sponsor: Sanofi

Target Recruit Count: 183

Registration Number: NCT00220272

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy